Progress in the care of familial hypercholesterolaemia: 2016

Medical Journal of Australia

Volumn 205, Issue 5, 2016, Pages 232-236

  Bell, Damon A ^a,b   Watts, Gerald F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE FREE SURVIVAL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC ANALYSIS; HEALTH CARE; HUMAN; PATIENT REFERRAL; POPULATION RISK; PREVALENCE; REVIEW; ADULT; ATHEROSCLEROSIS; AUSTRALIA; BLOOD; CHILD; COMPLICATION; COST BENEFIT ANALYSIS; DISEASE COURSE; GENETIC SCREENING; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ADULT; ATHEROSCLEROSIS; AUSTRALIA; CHILD; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GENETIC TESTING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; RISK ASSESSMENT; RISK FACTORS;

EID: 84987757912     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja16.00070     Document Type: Article

References (37)

1. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 2015; 243: 257-259.
2. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011; 12: 221-231.
3. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-3490.
4. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36: 560-565.
5. Watts GF, Shaw JE, Pang J, et al. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol 2015; 185: 69-71.
6. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146-2157.
7. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: 133-140.
8. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425-2437
9. Harada-Shiba M, Arai H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012; 19: 1043-1060.
10. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171: 309-325.
11. Bell DA, Pang J, Burrows S, et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Atherosclerosis 2015; 293: 93-100.
12. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 2014; 312: 1055-1057.
13. Klancar G, Groselj U, Kovac J, et al. Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol 2015; 66: 1250-1257.
14. Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 2014; 8: 390-400.
15. Bell DA, Hooper AJ, Bender R, et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann Clin Biochem 2012; 49(Pt 6): 534-537.
16. Bell DA, Bender R, Hooper AJ, et al. Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clin Chim Acta 2013; 422: 21-25.
17. Bell DA, Hooper AJ, Edwards G, et al. Detecting familial hypercholesterolaemia in the community: Impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis 2014; 234: 469-472.
18. Bell DA, Garton-Smith J, Vickery A, et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ 2014; 23: 309-313.
19. Kirke AB, Barbour RA, Burrows S, et al. Systematic detection of familial hypercholesterolaemia in primary health care: a community based prospective study of three methods. Heart Lung Circ 2015; 24: 250-256.
20. Vickery AW, Bell D, Garton-Smith J, et al. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. Heart Lung Circ 2014; 23: 1158-1164.
21. Troeung L, Arnold-Reed D, Ping-Delfos WCS, et al. A new electronic tool for identifying risk of familial hypercholesterolaemia in general practice. Heart 2016; 102: 855-861.
22. Khera AV, Won H-H, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67: 2578-2589.
23. Hooper AJ, Nguyen LT, Burnett JR, et al. Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis 2012; 224: 430-434.
24. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381: 1293-1301.
25. Futema M, Plagnol V, Li K, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 2014; 51: 537-544.
26. Norsworthy PJ, Vandrovcova J, Thomas ER, et al. Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study. BMC Med Genet 2014; 15: 70.
27. Watts GF, Wierzbicki AS. The hinterland of familial hypercholesterolaemia: what do we not know? Curr Opin Lipidol 2015; 26: 475-483.
28. Chan DC, Pang J, Hooper AJ, et al. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol 2015; 201: 633-638.
29. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013; 61: 1146-1156.
30. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63: 1982-1989.
31. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853.
32. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397.
33. Farnier M. PCSK9: from discovery to therapeutic applications. Arch Cardiovasc Dis 2014; 107: 58-66.
34. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015; 163: 40-51.
35. Page MM, Bell DA, Hooper AJ, et al. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract Res Clin Endocrinol Metab 2014; 28: 387-403.
36. Hammond E, Watts GF, Rubinstein Y, et al. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc 2013; 11: 134-139.
37. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015; 132: 2167-2192.